Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
Top Page
Bioxcel Therapeutics
(NASDAQ:BTAI)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▲(4.90% Upside)
Action:ReiteratedDate:01/20/26
The score is held down primarily by very weak financial performance (ongoing large losses, heavy cash burn, negative equity and high debt). Technical indicators are mixed and do not confirm a strong uptrend, while valuation lacks support due to negative earnings and no dividend. Offsetting factors include constructive corporate catalysts around IGALMI’s potential at-home label expansion and supportive clinical data.
Positive Factors
FDA‑approved lead product (IGALMI)
An FDA‑approved commercial product provides a durable revenue stream and regulatory validation. IGALMI establishes manufacturing, distribution and payer relationships, enabling further label expansions and commercial learning that support longer‑term revenue generation and partnership opportunities.
Negative Factors
Negative equity and high leverage
A negative equity position combined with sizable debt versus a small asset base is a structural constraint on financial flexibility. It raises refinancing and covenant risk, increases likelihood of dilutive capital raises, and can limit ability to fund R&D or scale commercial operations without costly external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA‑approved lead product (IGALMI)
An FDA‑approved commercial product provides a durable revenue stream and regulatory validation. IGALMI establishes manufacturing, distribution and payer relationships, enabling further label expansions and commercial learning that support longer‑term revenue generation and partnership opportunities.
Read all positive factors
Bioxcel Therapeutics (BTAI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$33.36M
Dividend YieldN/A
Average Volume (3M)1.58M
Price to Earnings (P/E)―
Beta (1Y)2.22
Revenue Growth-66.96%
EPS Growth71.83%
CountryUS
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding24,349,785
10 Day Avg. Volume1,230,633
30 Day Avg. Volume1,584,008
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.16
Price to Sales (P/S)6.69
P/FCF Ratio-0.21
Enterprise Value/Market Cap3.16
Enterprise Value/Revenue140.06
Enterprise Value/Gross Profit-366.99
Enterprise Value/Ebitda-2.05
Forecast
1Y Price Target
$8.00Price Target Upside459.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.63
Revenue Forecast (FY)$1.52M
Bioxcel Therapeutics Business Overview & Revenue Model
Company Description
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages ex...
How the Company Makes Money
Bioxcel Therapeutics generates revenue primarily through the commercialization of its drug candidates, once they receive regulatory approval. The company's revenue streams include direct sales of approved therapies and potential milestone payments...
Bioxcel Therapeutics Earnings Call Summary
Earnings Call Date:Nov 14, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted progress in clinical trials and significant financial improvements, such as reduced net loss and increased revenue over the nine-month period. However, challenges remain with decreased quarterly revenue, increased costs, and uncertainties regarding cash runway and financing.Positive Updates
Phase III Trials Progress
BioXcel announced milestones with two pivotal Phase III trials for BXCL501, targeting agitation in bipolar disorder, schizophrenia, and Alzheimer's dementia.
Negative Updates
Decrease in Quarterly Revenue
Net revenue from IGALMI decreased to $214,000 in Q3 2024 from $341,000 in Q3 2023, primarily due to the timing of reorders.
Read all updates
Q3-2024 Updates
Positive
Negative
Phase III Trials Progress
BioXcel announced milestones with two pivotal Phase III trials for BXCL501, targeting agitation in bipolar disorder, schizophrenia, and Alzheimer's dementia.
Read all positive updates
Company Guidance
During the recent BioXcel Therapeutics Q3 2024 earnings call, the company provided guidance on its ongoing clinical trials and financial performance. Vimal Mehta, CEO, highlighted the advancement of two pivotal Phase III trials for BXCL501, targeting agitation associated with bipolar disorder, schizophrenia in the home setting, and Alzheimer's dementia. The SERENITY At-Home trial aims for a 9 to 12-month duration with 26 active sites enrolling 200 patients. Financially, the company reported $214,000 in net revenue from IGALMI, marking a decline from $341,000 in Q3 2023, but a 89% year-over-year increase in net revenue for the nine months ended September 30, 2024. Operating expenses saw a reduction, with research and development expenses at $5.1 million, down from $19.6 million the previous year, and selling, general, and administrative expenses reduced to $7.7 million from $24.3 million. The company recorded a net loss of $13.7 million, significantly improved from $50.5 million in Q3 2023, and ended the quarter with $40.4 million in cash and cash equivalents. BioXcel is focused on strengthening its balance sheet and exploring strategic financing alternatives to support its trials through to data readout.Bioxcel Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 752.00K | 2.27M | 1.38M | 375.00K | 0.00 | 0.00 |
| Gross Profit | -287.00K | 123.00K | 120.00K | 355.00K | -297.00K | 0.00 |
| EBITDA | -51.29M | -44.16M | -165.42M | -157.22M | -107.00M | -82.11M |
| Net Income | -68.21M | -59.60M | -179.05M | -165.76M | -106.93M | -82.17M |
Balance Sheet | ||||||
| Total Assets | 44.79M | 38.34M | 73.70M | 205.85M | 239.44M | 219.94M |
| Cash, Cash Equivalents and Short-Term Investments | 37.32M | 29.85M | 65.22M | 193.72M | 232.97M | 213.12M |
| Total Debt | 109.29M | 102.95M | 101.38M | 94.16M | 1.40M | 1.64M |
| Total Liabilities | 133.71M | 131.44M | 130.21M | 129.08M | 17.77M | 13.24M |
| Stockholders Equity | -88.92M | -93.10M | -56.51M | 76.78M | 221.67M | 206.70M |
Cash Flow | ||||||
| Free Cash Flow | -58.21M | -72.03M | -155.03M | -135.48M | -82.60M | -66.67M |
| Operating Cash Flow | -58.21M | -72.03M | -155.01M | -135.34M | -82.15M | -66.35M |
| Investing Cash Flow | 0.00 | 0.00 | -20.00K | -139.00K | -445.00K | -316.00K |
| Financing Cash Flow | 55.15M | 36.66M | 26.52M | 96.24M | 102.45M | 247.36M |
Bioxcel Therapeutics Technical Analysis
Negative
1.43
Price Trends
1.63
Negative
1.75
Negative
2.28
Negative
Market Momentum
-0.05
Positive
38.62
Neutral
7.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTAI, the sentiment is Negative. The current price of 1.43 is below the 20-day moving average (MA) of 1.56, below the 50-day MA of 1.63, and below the 200-day MA of 2.28, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 38.62 is Neutral, neither overbought nor oversold. The STOCH value of 7.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BTAI.
Bioxcel Therapeutics Risk Analysis
Bioxcel Therapeutics disclosed 85 risk factors in its most recent earnings report. Bioxcel Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioxcel Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $46.50M | -0.64 | -62.53% | ― | ― | 35.80% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $33.36M | -0.29 | 71.83% | ― | -66.96% | 71.83% | |
46 Neutral | $370.23M | -1.12 | -4.88% | ― | 4121.12% | 83.30% | |
45 Neutral | $32.76M | -2.43 | -151.67% | ― | 11.11% | 20.65% | |
45 Neutral | $60.96M | -2.46 | -159.43% | ― | ― | 62.84% | |
44 Neutral | $12.62M | -0.64 | 780.31% | ― | -100.00% | 32.37% |
* Healthcare Sector Average
BTAI
Bioxcel Therapeutics
1.37
-0.94
-40.69%
ATNM
Actinium Pharmaceuticals
1.05
-0.84
-44.44%
KZR
Kezar Life Sciences
6.35
1.22
23.78%
ANVS
Annovis Bio
2.15
0.30
16.22%
BCAB
BioAtla
0.17
-0.22
-56.63%
IPSC
Century Therapeutics
2.06
1.51
275.91%
Bioxcel Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
BioXcel seeks FDA approval for at-home IGALMI use
Positive
Jan 20, 2026
On January 20, 2026, BioXcel Therapeutics announced that it had submitted a supplemental New Drug Application on January 14, 2026 to the U.S. Food and Drug Administration seeking approval for IGALMI’s use in the at-home setting for the acute...
Business Operations and StrategyExecutive/Board ChangesProduct-Related Announcements
BioXcel Therapeutics names interim CCO amid IGALMI expansion
Positive
Jan 12, 2026
On January 12, 2026, BioXcel Therapeutics announced the appointment of Mark Pavao as Interim Chief Commercial Officer to support the potential launch of its drug IGALMI for at-home use. The company plans to submit a supplemental New Drug Applicati...
Executive/Board ChangesShareholder MeetingsStock Split
BioXcel Therapeutics Holds Annual Stockholders Meeting
Neutral
Dec 15, 2025
On December 12, 2025, BioXcel Therapeutics held its annual stockholders meeting where 44.68% of the company’s outstanding common stock was represented. During the meeting, three Class I directors were elected, and several proposals were appr...
Product-Related Announcements
BioXcel Presents Phase 3 Study on BXCL501
Positive
Nov 10, 2025
On November 10, 2025, BioXcel Therapeutics announced the presentation of their Phase 3 study on BXCL501 at the Neuroscience Education Institute Conference. The study, conducted in a home setting, demonstrated that BXCL501 is safe and effective for...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.